Deucravacitinib Shows Efficacy Signal in Cutaneous Lupus Erythematosus
Deucravacitinib (Sotyktu, Bristol-Myers Squibb) may help improve cutaneous manifestations in patients with systemic lupus erythematosus, according to a late-breaking study presented at MauiDerm 2024. Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor approved in multiple countries for the treatment of adults with moderate to severe plaque psoriasis. In the 48-week, double-blind, phase […]